AstraZeneca Notches Prostate Cancer Success With Lynparza

Date : 09/30/2019 @ 2:59PM
Source : Dow Jones News
Stock : Astrazeneca Plc (AZN)
Quote : 7217.0  -58.0 (-0.80%) @ 4:35PM
Astrazeneca share price Chart

AstraZeneca Notches Prostate Cancer Success With Lynparza

Astrazeneca (LSE:AZN)
Historical Stock Chart

3 Months : From Sep 2019 to Dec 2019

Click Here for more Astrazeneca Charts.

By Carlo Martuscelli


AstraZeneca PLC (AZN.LN) said Monday that a study of its cancer drug Lynparza used as a treatment for metastatic prostate cancer met its target.

The phase 3 Profound study showed that patients with certain genetic mutations who were administered Lynparza lived longer without their disease progressing compared with those given hormonal treatments.

The drug was able to reduce the risk of disease progression or death by 66%, Astra said.

Greg Rossi, vice president of the oncology franchise at the FTSE 100-listed pharmaceutical company, told Dow Jones Newswires that the impact was substantial.

Lynparza was being tested in patients that had mutations in a group of genes associated with cells' DNA repair mechanism. He said that Lynparza is able to exploit this vulnerability, and further impair the genetic function of cancer cells in order to kill them.

It is estimated that between 20% and 25% of patients with metastatic prostate cancer have at least one mutation in this group of genes, he said.

Mr. Rossi said that the company is targeting expanded U.S. approval for the drug in 2020. Astra developed Lynparza in collaboration with Merck & Co. (MRK).


Write to Carlo Martuscelli at


(END) Dow Jones Newswires

September 30, 2019 10:44 ET (14:44 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191215 21:59:48